Credit Suisse Reiterates “Neutral” Rating for Myriad Genetics (MYGN)
Myriad Genetics (NASDAQ:MYGN)‘s stock had its “neutral” rating reaffirmed by equities researchers at Credit Suisse in a research report issued on Friday. They currently have a $35.00 price target on the stock, down from their previous price target of $40.00. Credit Suisse’s price target would suggest a potential downside of 2.88% from the company’s current price.
Myriad Genetics (NASDAQ:MYGN) opened at 36.09 on Friday. Myriad Genetics has a 1-year low of $20.02 and a 1-year high of $42.50. The stock’s 50-day moving average is $37.67 and its 200-day moving average is $36.14. The company has a market cap of $2.685 billion and a price-to-earnings ratio of 16.02. Myriad Genetics also saw some unusual options trading on Tuesday. Investors bought 557 call options on the company. This represents an increase of 220% compared to the typical volume of 174 call options.
Myriad Genetics (NASDAQ:MYGN) last released its earnings data on Tuesday, August 12th. The company reported $0.48 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.46 by $0.02. The company had revenue of $188.80 million for the quarter, compared to the consensus estimate of $187.68 million. Analysts expect that Myriad Genetics will post $2.01 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at SunTrust raised their price target on shares of Myriad Genetics from $22.00 to $26.00 in a research note on Monday, July 14th. Separately, analysts at RBC Capital raised their price target on shares of Myriad Genetics from $31.00 to $40.00 in a research note on Monday, June 30th. They now have a “sector perform” rating on the stock. Finally, analysts at Macquarie reiterated a “neutral” rating on shares of Myriad Genetics in a research note on Thursday, June 5th. They now have a $36.00 price target on the stock, down previously from $38.00. One analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $34.99.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.